These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 29936149

  • 1. Neuroprotective effect of epalrestat mediated through oxidative stress markers, cytokines and TAU protein levels in diabetic rats.
    Jaiswal S, Mishra S, Torgal SS, Shengule S.
    Life Sci; 2018 Aug 15; 207():364-371. PubMed ID: 29936149
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N, Kawamori R, Fukuda M, Shigeta Y, Aldose Reductase Inhibitor-Diabetes Complications Trial Study Group.
    Diabet Med; 2012 Dec 15; 29(12):1529-33. PubMed ID: 22507139
    [Abstract] [Full Text] [Related]

  • 5. Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells.
    Yama K, Sato K, Abe N, Murao Y, Tatsunami R, Tampo Y.
    Redox Biol; 2015 Dec 15; 4():87-96. PubMed ID: 25529839
    [Abstract] [Full Text] [Related]

  • 6. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA, Borja NL.
    Pharmacotherapy; 2008 May 15; 28(5):646-55. PubMed ID: 18447661
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
    Steele JW, Faulds D, Goa KL.
    Drugs Aging; 1993 May 15; 3(6):532-55. PubMed ID: 8312678
    [Abstract] [Full Text] [Related]

  • 9. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K, Sato N, Sato K, Shimizu H, Mori M.
    Endocrinology; 1998 Aug 15; 139(8):3404-8. PubMed ID: 9681489
    [Abstract] [Full Text] [Related]

  • 10. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N.
    Diabetes Care; 2000 Oct 15; 23(10):1539-44. PubMed ID: 11023149
    [Abstract] [Full Text] [Related]

  • 11. Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats.
    Yang BB, Hong ZW, Zhang Z, Yu W, Song T, Zhu LL, Jiang HS, Chen GT, Chen Y, Dai YT.
    Int J Impot Res; 2019 Mar 15; 31(2):97-104. PubMed ID: 30214006
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T, Saita K, Furukawa S, Ohta M, Hayashi K, Matsukura S.
    Exp Neurol; 1998 Jun 15; 151(2):215-20. PubMed ID: 9628756
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
    Kurata C, Okayama K, Wakabayashi Y, Shouda S, Mikami T, Tawarahara K, Sugiyama T.
    J Nucl Med; 1997 Nov 15; 38(11):1677-80. PubMed ID: 9374332
    [Abstract] [Full Text] [Related]

  • 16. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
    Sasaki H, Naka K, Kishi Y, Furuta M, Sanke T, Mukoyama M, Nanjo K.
    Exp Neurol; 1997 Aug 15; 146(2):466-70. PubMed ID: 9270057
    [Abstract] [Full Text] [Related]

  • 17. Effects of aldose reductase inhibition with epalrestat on diabetes-induced changes in rat isolated atria.
    Booth RJ, Hodgson WC.
    Clin Exp Pharmacol Physiol; 1993 Apr 15; 20(4):207-13. PubMed ID: 8485921
    [Abstract] [Full Text] [Related]

  • 18. A dual-acting aldose reductase inhibitor impedes oxidative and carbonyl stress in tissues of fructose- and streptozotocin-induced rats: comparison with antioxidant stobadine.
    Kaya A, Ceylan AF, Kavutcu M, Santamaria A, Šoltésová Prnová M, Stefek M, Karasu Ç.
    Drug Chem Toxicol; 2024 Sep 15; 47(5):710-720. PubMed ID: 37795621
    [Abstract] [Full Text] [Related]

  • 19. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
    Elmazoglu Z, Prnova MS, Stefek M, Ceylan AF, Aschner M, Rangel-López E, Santamaria A, Karasu C.
    Neurotox Res; 2021 Jun 15; 39(3):588-597. PubMed ID: 33713301
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.